Alloantigen expression on non-hematopoietic cells reduces graft-versus-leukemia effects in mice

Shoji Asakura, Daigo Hashimoto, Shuichiro Takashima, Haruko Sugiyama, Yoshinobu Maeda, Koichi Akashi, Mitsune Tanimoto, Takanori Teshima

Research output: Contribution to journalArticle

53 Citations (Scopus)

Abstract

Allogeneic hematopoietic stem cell transplantation (HSCT) is used effectively to treat a number of hematological malignancies. Its beneficial effects rely on donor-derived T cell-targeted leukemic cells, the so-called graft-versus-leukemia (GVL) effect. Induction of GVL is usually associated with concomitant development of graft-versus-host disease (GVHD), a major complication of allogeneic HSCT. The T cells that mediate GVL and GVHD are activated by alloantigen presented on host antigen-presenting cells of hematopoietic origin, and it is not well understood how alloantigen expression on non-hematopoietic cells affects GVL activity. Here we show, in mouse models of MHC-matched, minor histocompatibility antigen-mismatched bone marrow transplantation, that alloantigen expression on host epithelium drives donor T cells into apoptosis and dysfunction during GVHD, resulting in a loss of GVL activity. During GVHD, programmed death-1 (PD-1) and PD ligand-1 (PD-L1), molecules implicated in inducing T cell exhaustion, were upregulated on activated T cells and the target tissue, respectively, suggesting that the T cell defects driven by host epithelial alloantigen expression might be mediated by the PD-1/PD-L1 pathway. Consistent with this, blockade of PD-1/PD-L1 interactions partially restored T cell effector functions and improved GVL. These results elucidate a previously unrecognized significance of alloantigen expression on non-hematopoietic cells in GVL and suggest that separation of GVL from GVHD for more effective HSCT may be possible in human patients.

Original languageEnglish
Pages (from-to)2370-2378
Number of pages9
JournalJournal of Clinical Investigation
Volume120
Issue number7
DOIs
Publication statusPublished - Jul 1 2010

Fingerprint

Isoantigens
Leukemia
Graft vs Host Disease
Transplants
T-Lymphocytes
Hematopoietic Stem Cell Transplantation
Ligands
Minor Histocompatibility Antigens
Tissue Donors
Antigen-Presenting Cells
Hematologic Neoplasms
Bone Marrow Transplantation
Epithelium
Apoptosis

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Asakura, S., Hashimoto, D., Takashima, S., Sugiyama, H., Maeda, Y., Akashi, K., ... Teshima, T. (2010). Alloantigen expression on non-hematopoietic cells reduces graft-versus-leukemia effects in mice. Journal of Clinical Investigation, 120(7), 2370-2378. https://doi.org/10.1172/JCI39165

Alloantigen expression on non-hematopoietic cells reduces graft-versus-leukemia effects in mice. / Asakura, Shoji; Hashimoto, Daigo; Takashima, Shuichiro; Sugiyama, Haruko; Maeda, Yoshinobu; Akashi, Koichi; Tanimoto, Mitsune; Teshima, Takanori.

In: Journal of Clinical Investigation, Vol. 120, No. 7, 01.07.2010, p. 2370-2378.

Research output: Contribution to journalArticle

Asakura, S, Hashimoto, D, Takashima, S, Sugiyama, H, Maeda, Y, Akashi, K, Tanimoto, M & Teshima, T 2010, 'Alloantigen expression on non-hematopoietic cells reduces graft-versus-leukemia effects in mice', Journal of Clinical Investigation, vol. 120, no. 7, pp. 2370-2378. https://doi.org/10.1172/JCI39165
Asakura, Shoji ; Hashimoto, Daigo ; Takashima, Shuichiro ; Sugiyama, Haruko ; Maeda, Yoshinobu ; Akashi, Koichi ; Tanimoto, Mitsune ; Teshima, Takanori. / Alloantigen expression on non-hematopoietic cells reduces graft-versus-leukemia effects in mice. In: Journal of Clinical Investigation. 2010 ; Vol. 120, No. 7. pp. 2370-2378.
@article{b91b7abcb6904768a7a44902850c355b,
title = "Alloantigen expression on non-hematopoietic cells reduces graft-versus-leukemia effects in mice",
abstract = "Allogeneic hematopoietic stem cell transplantation (HSCT) is used effectively to treat a number of hematological malignancies. Its beneficial effects rely on donor-derived T cell-targeted leukemic cells, the so-called graft-versus-leukemia (GVL) effect. Induction of GVL is usually associated with concomitant development of graft-versus-host disease (GVHD), a major complication of allogeneic HSCT. The T cells that mediate GVL and GVHD are activated by alloantigen presented on host antigen-presenting cells of hematopoietic origin, and it is not well understood how alloantigen expression on non-hematopoietic cells affects GVL activity. Here we show, in mouse models of MHC-matched, minor histocompatibility antigen-mismatched bone marrow transplantation, that alloantigen expression on host epithelium drives donor T cells into apoptosis and dysfunction during GVHD, resulting in a loss of GVL activity. During GVHD, programmed death-1 (PD-1) and PD ligand-1 (PD-L1), molecules implicated in inducing T cell exhaustion, were upregulated on activated T cells and the target tissue, respectively, suggesting that the T cell defects driven by host epithelial alloantigen expression might be mediated by the PD-1/PD-L1 pathway. Consistent with this, blockade of PD-1/PD-L1 interactions partially restored T cell effector functions and improved GVL. These results elucidate a previously unrecognized significance of alloantigen expression on non-hematopoietic cells in GVL and suggest that separation of GVL from GVHD for more effective HSCT may be possible in human patients.",
author = "Shoji Asakura and Daigo Hashimoto and Shuichiro Takashima and Haruko Sugiyama and Yoshinobu Maeda and Koichi Akashi and Mitsune Tanimoto and Takanori Teshima",
year = "2010",
month = "7",
day = "1",
doi = "10.1172/JCI39165",
language = "English",
volume = "120",
pages = "2370--2378",
journal = "Journal of Clinical Investigation",
issn = "0021-9738",
publisher = "The American Society for Clinical Investigation",
number = "7",

}

TY - JOUR

T1 - Alloantigen expression on non-hematopoietic cells reduces graft-versus-leukemia effects in mice

AU - Asakura, Shoji

AU - Hashimoto, Daigo

AU - Takashima, Shuichiro

AU - Sugiyama, Haruko

AU - Maeda, Yoshinobu

AU - Akashi, Koichi

AU - Tanimoto, Mitsune

AU - Teshima, Takanori

PY - 2010/7/1

Y1 - 2010/7/1

N2 - Allogeneic hematopoietic stem cell transplantation (HSCT) is used effectively to treat a number of hematological malignancies. Its beneficial effects rely on donor-derived T cell-targeted leukemic cells, the so-called graft-versus-leukemia (GVL) effect. Induction of GVL is usually associated with concomitant development of graft-versus-host disease (GVHD), a major complication of allogeneic HSCT. The T cells that mediate GVL and GVHD are activated by alloantigen presented on host antigen-presenting cells of hematopoietic origin, and it is not well understood how alloantigen expression on non-hematopoietic cells affects GVL activity. Here we show, in mouse models of MHC-matched, minor histocompatibility antigen-mismatched bone marrow transplantation, that alloantigen expression on host epithelium drives donor T cells into apoptosis and dysfunction during GVHD, resulting in a loss of GVL activity. During GVHD, programmed death-1 (PD-1) and PD ligand-1 (PD-L1), molecules implicated in inducing T cell exhaustion, were upregulated on activated T cells and the target tissue, respectively, suggesting that the T cell defects driven by host epithelial alloantigen expression might be mediated by the PD-1/PD-L1 pathway. Consistent with this, blockade of PD-1/PD-L1 interactions partially restored T cell effector functions and improved GVL. These results elucidate a previously unrecognized significance of alloantigen expression on non-hematopoietic cells in GVL and suggest that separation of GVL from GVHD for more effective HSCT may be possible in human patients.

AB - Allogeneic hematopoietic stem cell transplantation (HSCT) is used effectively to treat a number of hematological malignancies. Its beneficial effects rely on donor-derived T cell-targeted leukemic cells, the so-called graft-versus-leukemia (GVL) effect. Induction of GVL is usually associated with concomitant development of graft-versus-host disease (GVHD), a major complication of allogeneic HSCT. The T cells that mediate GVL and GVHD are activated by alloantigen presented on host antigen-presenting cells of hematopoietic origin, and it is not well understood how alloantigen expression on non-hematopoietic cells affects GVL activity. Here we show, in mouse models of MHC-matched, minor histocompatibility antigen-mismatched bone marrow transplantation, that alloantigen expression on host epithelium drives donor T cells into apoptosis and dysfunction during GVHD, resulting in a loss of GVL activity. During GVHD, programmed death-1 (PD-1) and PD ligand-1 (PD-L1), molecules implicated in inducing T cell exhaustion, were upregulated on activated T cells and the target tissue, respectively, suggesting that the T cell defects driven by host epithelial alloantigen expression might be mediated by the PD-1/PD-L1 pathway. Consistent with this, blockade of PD-1/PD-L1 interactions partially restored T cell effector functions and improved GVL. These results elucidate a previously unrecognized significance of alloantigen expression on non-hematopoietic cells in GVL and suggest that separation of GVL from GVHD for more effective HSCT may be possible in human patients.

UR - http://www.scopus.com/inward/record.url?scp=77954987288&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77954987288&partnerID=8YFLogxK

U2 - 10.1172/JCI39165

DO - 10.1172/JCI39165

M3 - Article

VL - 120

SP - 2370

EP - 2378

JO - Journal of Clinical Investigation

JF - Journal of Clinical Investigation

SN - 0021-9738

IS - 7

ER -